|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
DeSantis C, Ma J, Bryan L and Jemal A:
Breast cancer statistics, 2013. CA Cancer J Clin. 64:52–62. 2014.
View Article : Google Scholar
|
|
3
|
Abu J, Batuwangala M, Herbert K and
Symonds P: Retinoic acid and retinoid receptors: potential
chemopreventive and therapeutic role in cervical cancer. Lancet
Oncol. 6:712–720. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
De Luca LM, Darwiche N, Celli G, Kosa K,
Jones C, Ross S and Chen LC: Vitamin A in epithelial
differentiation and skin carcinogenesis. Nutr Rev. 52:S45–S52.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gudas LJ, Sporn MB and Roberts AB:
Cellular biology and biochemistry of the retinoids. The Retinoids:
Biology, Chemistry and Medicine. Sporn MB, Roberts AB and Goodman
DS: Raven Press, Ltd; New York: pp. 443–520. 1994
|
|
6
|
Niles RM: Recent advances in the use of
vitamin A (retinoids) in the prevention and treatment of cancer.
Nutrition. 16:1084–1089. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Simeone AM and Tari AM: How retinoids
regulate breast cancer cell proliferation and apoptosis. Cell Mol
Life Sci. 61:1475–1484. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Love JM and Gudas LJ: Vitamin A,
differentiation and cancer. Curr Opin Cell Biol. 6:825–831. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Vivat-Hannah V, You D, Rizzo C, Daris JP,
Lapointe P, Zusi FC, Marinier A, Lorenzi MV and Gottardis MM:
Synergistic cytotoxicity exhibited by combination treatment of
selective retinoid ligands with taxol (Paclitaxel). Cancer Res.
61:8703–8711. 2001.PubMed/NCBI
|
|
10
|
Altucci L, Rossin A, Raffelsberger W,
Reitmair A, Chomienne C and Gronemeyer H: Retinoic acid-induced
apoptosis in leukemia cells is mediated by paracrine action of
tumor-selective death ligand TRAIL. Nat Med. 7:680–686. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chambon P: A decade of molecular biology
of retinoic acid receptors. FASEB J. 10:940–954. 1996.PubMed/NCBI
|
|
12
|
Giguère V: Retinoic acid receptors and
cellular retinoid binding proteins: Complex interplay in retinoid
signaling. Endocr Rev. 15:61–79. 1994.PubMed/NCBI
|
|
13
|
Zusi FC, Lorenzi MV and Vivat-Hannah V:
Selective retinoids and rexinoids in cancer therapy and
chemoprevention. Drug Discov Today. 7:1165–1174. 2002. View Article : Google Scholar
|
|
14
|
Thacher SM, Vasudevan J and Chandraratna
RA: Therapeutic applications for ligands of retinoid receptors.
Curr Pharm Des. 6:25–58. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nagpal S and Chandraratna RA: Recent
developments in receptor-selective retinoids. Curr Pharm Des.
6:919–931. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kong G, Kim HT, Wu K, et al: The retinoid
X receptor-selective retinoid, LGD1069, downregulates
cyclooxygenase-2 expression in human breast cells through
transcription factor crosstalk: implications for molecular-based
chemoprevention. Cancer Res. 65:3462–3469. 2005.PubMed/NCBI
|
|
17
|
Nagy L, Thomazy VA, Heyman RA and Davies
PJ: Retinoid-induced apoptosis in normal and neoplastic tissues.
Cell Death Differ. 5:11–19. 1998. View Article : Google Scholar
|
|
18
|
Lippman SM and Lotan R: Advances in the
development of retinoids as chemopreventive agents. J Nutr.
130(Suppl 2): 479S–482S. 2000.PubMed/NCBI
|
|
19
|
Gottardis MM, Bischoff ED, Shirley MA,
Wagoner MA, Lamph WW and Heyman RA: Chemoprevention of mammary
carcinoma by LGD1069 (Targretin): an RXR-selective ligand. Cancer
Res. 56:5566–5570. 1996.PubMed/NCBI
|
|
20
|
Wu K, Zhang Y, Xu XC, et al: The retinoid
X receptor-selective retinoid, LGD1069, prevents the development of
estrogen receptor-negative mammary tumors in transgenic mice.
Cancer Res. 62:6376–6380. 2002.PubMed/NCBI
|
|
21
|
Wu K, Kim HT, Rodriquez JL, et al:
Suppression of mammary tumorigenesis in transgenic mice by the
RXR-selective retinoid, LGD1069. Cancer Epidemiol Biomarkers Prev.
11:467–474. 2002.PubMed/NCBI
|
|
22
|
Crowe DL and Chandraratna RA: A retinoid X
receptor (RXR)-selective retinoid reveals that RXR-alpha is
potentially a therapeutic target in breast cancer cell lines and
that it potentiates antiproliferative and apoptotic responses to
peroxisome proliferator-activated receptor ligands. Breast Cancer
Res. 6:R546–R555. 2004. View
Article : Google Scholar
|
|
23
|
Farol LT and Hymes KB: Bexarotene: a
clinical review. Expert Rev Anticancer Ther. 4:180–188. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rigas JR and Dragnev KH: Emerging role of
rexinoids in non-small cell lung cancer: focus on bexarotene.
Oncologist. 10:22–33. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ma Y, Koza-Taylor PH, DiMattia DA, Hames
L, Fu H, Dragnev KH, Turi T, Beebe JS, Freemantle SJ and Dmitrovsky
E: Microarray analysis uncovers retinoid targets in human bronchial
epithelial cells. Oncogene. 22:4924–4932. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li G, Walch E, Yang X, Lippman SM and
Clifford JL: Cloning and characterization of the human retinoid X
receptor alpha gene: conservation of structure with the mouse
homolog. Biochem Biophys Res Commun. 69:54–57. 2000. View Article : Google Scholar
|
